Position in RPRX
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$28,158
+$5,477 QoQ
Shares Held
587
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2020
8 quarters on record
Voting authority
Sole 14%
Shared 0%
None 86%
Common Shares in RPRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Manchester Capital Management LLC holds $538,294 across 24 Biotechnology names. RPRX ranks #5 (5.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
396 | $176,829 | |
| 2 | INSM |
INSMED Inc
|
1,017 | $166,299 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
46 | $35,541 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
86 | $28,454 | |
| 5 | RPRX |
Royalty Pharma plc
This page
|
587 | $28,158 | |
| 6 | ABVX |
Abivax S.A.
|
200 | $22,270 | |
| 7 | CRSP |
CRISPR Therapeutics AG
|
400 | $19,028 | |
| 8 | MRNA |
Moderna, Inc.
|
372 | $18,897 |
All Filings in RPRX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $28,158 | 587 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $22,681 | 587 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $19,333 | 548 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $20,465 | 568 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $18,148 | 583 | Shares | Sole | 2025-05-09 | |
| 2024-12-31 | $10,408 | 408 | Shares | Sole | 2025-01-30 | |
| 2021-12-31 | $9,484 | 238 | Shares | Sole | 2022-02-10 | |
| 2020-12-31 | $1,651 | 33 | Shares | Sole | 2021-02-16 | |
| No filing history on record for this holder in this stock. | ||||||